Skip to the content
  • 719-347-5400
  • info@realmofcaring.org
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Donate
  • Register
  • Login
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Donate
  • Register
  • Login
  • ∆9-tetrahydrocannabinol (THC), analgesia, Cannabidiol (CBD), Cannabinoid receptor/s, Cannabis, Endocannabinoid/s, inflammatory pain, neuropathic pain
Loading...

Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes

Abstract Cannabis extracts and synthetic cannabinoids are still widely considered illegal substances. Preclinical and clinical studies have suggested that they may result useful to treat diverse diseases, including those related with acute or chronic pain. The discovery of cannabinoid receptors, their endogenous ligands, and the machinery for the synthesis, transport, and degradation of these retrograde messengers, has equipped us with neurochemical tools for novel drug design. Agonist-activated cannabinoid receptors, modulate nociceptive thresholds, inhibit release of pro-inflammatory molecules, and display synergistic effects with other systems that influence analgesia, especially the endogenous opioid system. Cannabinoid receptor agonists have shown therapeutic value against inflammatory and neuropathic pains,...
Read More

Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection

Background: Cannabinoid use could potentially alter HIV RNA levels by two mechanisms: immune modulation or cannabinoid– protease inhibitor interactions (because both share cytochrome P-450 metabolic pathways). Objective: To determine the short-term effects of smoked marijuana on the viral load in HIV-infected patients. Design: Randomized, placebo-controlled, 21-day intervention trial. Setting: The inpatient General Clinical Research Center at the San Francisco General Hospital, San Francisco, California. Participants: 67 patients with HIV-1 infection. Intervention: Participants were randomly assigned to a 3.95%- tetrahydrocannabinol marijuana cigarette, a 2.5-mg dronabinol (delta-9-tetrahydrocannabinol) capsule, or a placebo capsule three times daily before meals. Measurements: HIV RNA levels, CD4 and CD8 cell subsets,...
Read More

Smoked cannabis for chronic neuropathic pain: a randomized controlled trial

Abstract Background Chronic neuropathic pain affects 1%–2% of the adult population and is often refractory to standard pharmacologic treatment. Patients with chronic pain have reported using smoked cannabis to relieve pain, improve sleep and improve mood. Methods Adults with post-traumatic or postsurgical neuropathic pain were randomly assigned to receive cannabis at four potencies (0%, 2.5%, 6% and 9.4% tetrahydrocannabinol) over four 14-day periods in a crossover trial. Participants inhaled a single 25-mg dose through a pipe three times daily for the first five days in each cycle, followed by a nine-day washout period. Daily average pain intensity was measured using an 11-point numeric rating...
Read More

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial

Background: Spasticity is a common and poorly controlled symptom of multiple sclerosis. Our objective was to determine the short-term effect of smoked cannabis on this symptom. Methods: We conducted a placebo-controlled, crossover trial involving adult patients with multiple sclerosis and spasticity. We re cruited participants from a regional clinic or by referral from specialists. We randomly assigned participants to either the intervention (smoked cannabis, once daily for three days) or control (identical placebo cigarettes, once daily for three days). Each participant was assessed daily before and after treatment. After a washout interval of 11 days, participants crossed over to the opposite group. Our primary...
Read More

Survey on Cannabis Use in Parkinson’s Disease: Subjective Improvement of Motor Symptoms

An anonymous questionnaire sent to all patients attending the Prague Movement Disorder Centre revealed that 25% of 339 respondents had taken cannabis and 45.9% of these described some form of benefit.
Read More

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity

Abstract A large proportion of patients with multiple sclerosis (MS) have spasticity, which has a marked impact on their quality of life. Anecdotal evidence suggests a beneficial effect of cannabis on spasticity as well as pain. Recently, randomized, double-blind, placebo-controlled studies have confirmed the clinical efficacy of cannabinoids for the treatment of spasticity in patients with MS. Based on these data, nabiximols (Sativex), a 1:1 mix of Δ-9-tetrahydrocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, received approval for treating MS-related spasticity in various countries around the globe. In this article we review the current understanding of cannabinoid biology and the value of cannabinoids as a...
Read More

Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine

Evidence for an analgesic interaction between delta-9-tetrahydrocannabinol (Δ9 -THC) and morphine was sought using an experimental pain model applied to normal volunteers. The study incorporated a double blinded, four treatment, four period, four sequence, crossover design. Subjects received Δ9 -THC 5 mg orally or placebo and 90 min later morphine 0.02 mg/kg intravenously or placebo. Fifteen minutes later subjects rated the pain associated with the application of thermal stimuli to skin using two visual analog scales, one for the sensory and one for the affective aspects of pain. Among sensory responses, neither morphine nor Δ9 -THC had a significant effect at the doses used,...
Read More

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects

Abstract Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol and phytol. Terpenoids share a precursor with phytocannabinoids, and are all flavour and fragrance components common to human...
Read More

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities

Abstract Human tissues express cannabinoid CB(1) and CB(2) receptors that can be activated by endogenously released 'endocannabinoids' or exogenously administered compounds in a manner that reduces the symptoms or opposes the underlying causes of several disorders in need of effective therapy. Three medicines that activate cannabinoid CB(1)/CB(2) receptors are now in the clinic: Cesamet (nabilone), Marinol (dronabinol; Δ(9)-tetrahydrocannabinol (Δ(9)-THC)) and Sativex (Δ(9)-THC with cannabidiol). These can be prescribed for the amelioration of chemotherapy-induced nausea and vomiting (Cesamet and Marinol), stimulation of appetite (Marinol) and symptomatic relief of cancer pain and/or management of neuropathic pain and spasticity in adults with multiple sclerosis (Sativex). This review...
Read More

The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids

As a therapeutic agent, most people are familiar with the palliative effects of the primary psychoactive constituent of Cannabis sativa (CS), Δ9 -tetrahydrocannabinol (THC), a molecule active at both the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor subtypes. Through the activation primarily of CB1 receptors in the central nervous system, THC can reduce nausea, emesis and pain in cancer patients undergoing chemotherapy. During the last decade, however, several studies have now shown that CB1 and CB2 receptor agonists can act as direct antitumor agents in a variety of aggressive cancers. In addition to THC, there are many other cannabinoids found in CS, and...
Read More
« Previous 1 … 94 95 96 97 98 Next »

REGISTER WITH RoC TODAY!

Realm of Caring focuses on research, education, building community, and improving quality of life. We are an educational resource for consumers, physicians, scientists, governments and the media.
Register now
  • PO Box 15224, Colorado Springs, CO 80935
  • 719-347-5400
  • info@realmofcaring.org

Copyright © 2024 / Realm of Caring Foundation, Inc

  • Privacy
  • Disclaimer

Open the following in new tabs if you:

If you are already a user: Client Login

If you are not, then register: Client Registration

Once Logged in, click below to refresh the page.